You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

Authors

  • Sven Borchmann Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Carolin Selenz Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Mia Lohmann Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Hanna Ludwig Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Asmae Gassa Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Johannes Brägelmann Mildred Scheel School of Oncology, University Hospital Cologne, Medical Faculty, Cologne, Germany PubMed articlesGoogle scholar articles
  • Philipp Lohneis Institute of Pathology, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Lydia Meder Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Julia Mattlener Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Sara Breid Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Marieke Nill Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Jana Fassunke Institute of Pathology, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Amy J. Wisdom Department of Radiation Oncology and Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Anik Compes Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Birgit Gathof Institute of Transfusion Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Hakan Alakus Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • David Kirsch Department of Radiation Oncology and Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Khosro Hekmat Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Reinhard Büttner Institute of Pathology, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • H. Christian Reinhardt Department of Hematology and Stem Cell Transplantation, University Hospital Essen,University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany PubMed articlesGoogle scholar articles
  • Michael Hallek Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Roland T. Ullrich Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sven Borchmann, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne, Kerpener Str. 62, 50931 Cologne, Germany; sven.borchmann{at}uk-koeln.de; Prof Roland T. Ullrich, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne, Kerpener Str. 62, 50931 Cologne, Germany; roland.ullrich{at}uk-koeln.de
View Full Text

Citation

Borchmann S, Selenz C, Lohmann M, et al
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
Journal for ImmunoTherapy of Cancer 2022;10:e004781. doi: 10.1136/jitc-2022-004781

Publication history

  • Accepted September 18, 2022
  • First published October 12, 2022.
Online issue publication 
December 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.